LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L), a global biopharmaceutical company and KYM Biosciences Inc. have entered into a global exclusive licence agreement whereby AstraZeneca would be responsible
The prevalence of gastric cancer has been rising since the past few years, which prompts the growing demand for treatment options. The increasing prevalence of cancer, the robust pipeline,
Hutchmed Ltd - Hong Kong-based biopharmaceutical company - Reports positive top-line results for its gastric cancer treatment fruquintinib, when combined with paclitaxel. Explains the drug met one. | November 14, 2022